Publications
2022
- Calendrier de vaccination contre les virus du papillome humain pour les personnes âgées de 18 ans et plus au Québec
- Fardeau de la varicelle et du zona à la suite de l’introduction du programme de vaccination contre la varicelle à une puis à deux doses au Québec
- Vaccination contre l’hépatite virale A suite à une éclosion à Nunavik
2021
2020
- Vaccination contre l’hépatite A des enfants nés d’avril 2013 à mai 2019
- Les activités de vaccination en période de pandémie de COVID-2019 - Version 2.0 du 6 mai 2020
- Mesures à mettre en place pour les hôtels qui accueilleront des personnes en isolement volontaire ou obligatoire (asymptomatiques) ou des personnes atteintes de COVID-19 ou sous investigation qui ne peuvent être isolées à la maison
Publications
2022
- The impact of influenza on the ability to work, volunteer and provide care: results from an online survey of Canadian adults 50 years and older
- Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada
- Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
2021
- Sexual behavior, clinical outcomes and attendance of cervical cancer screening by HPV vaccinated and unvaccinated sexually active women
- COVID-19's Impact on Willingness to Be Vaccinated against Influenza and COVID-19 during the 2020/2021 Season: Results from an Online Survey of Canadian Adults 50 Years and Older
2019
- The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?
- Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial
- A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine
2018
- Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial
- Herpes Zoster Burden in Canadian Provinces: A Narrative Review and Comparison with Quebec Provincial Data
- Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis
- Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact
- Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine